Trial · NCT00880594
Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine
NCT00880594, Not applicable, Terminated, Washington University School of Medicine; results first posted 2026-01-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine. Trials, record NCT00880594. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00880594
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine
- NCT number
- NCT00880594
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 18 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Desipramine
- First posted
- 2009-04-14
- Last updated
- 2026-01-22
- Results first posted
- 2026-01-22
- Limitations and caveats
- Desipramine open-label completion target not achieved
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MRI Blood Oxygen Level Dependent (BOLD) Activation CONTRASTS (in Prespecified Regions of Interest (ROI) in VOXELS | 1 month | CONTRASTS (comparisons of study group BOLD activations vs rest) are the outcome of interest. Voxel-wise comparisons (ANOVAs) were performed to determine differences in activations between groups within these regions. First level analyses of rectal balloon distensions experienced by subjects were modeled as box car functions then convolved with the canonical hemodynamic response function (HRF). For the second level analyses, differences in brain activation while experiencing both high and low painful rectal balloon distensions between IBS patients with High somatization vs Low somatization were examined with two-sample t-tests utilizing contrast images generated from the first level analysis. Unconventionally, these inferential statistics are regarded as the primary outcome in the study. Accordingly individual group level BOLD values where not recorded or evaluated separately in the cohorts. These data are not available, and cannot be reported "per Arm". |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | MRI Blood Oxygen Level Dependent (BOLD) Activation CONTRASTS (in Prespecified Regions of Interest (ROI) in VOXELS | 1 month | arbitrary unit | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| MRI Blood Oxygen Level Dependent (BOLD) Activation CONTRASTS (in Prespecified Regions of Interest (ROI) in VOXELS | IBS-High Somatization | Left insula activation contrast, Montreal Neurological Institute x,y,z coordinates (-28.5, 9, 19.5) | 0.02 | Standard Deviation 0.045 | arbitrary unit |
| MRI Blood Oxygen Level Dependent (BOLD) Activation CONTRASTS (in Prespecified Regions of Interest (ROI) in VOXELS | IBS-Low Somatization | Left insula activation contrast, Montreal Neurological Institute x,y,z coordinates (-28.5, 9, 19.5) | -0.09 | Standard Deviation 0.07 | arbitrary unit |
| MRI Blood Oxygen Level Dependent (BOLD) Activation CONTRASTS (in Prespecified Regions of Interest (ROI) in VOXELS | IBS-High Somatization | Right insula activation contrast, Montreal Neurological Institute x,y,z coordinates (27, -1.5, 15) | 0.02 | Standard Deviation 0.04 | arbitrary unit |
| MRI Blood Oxygen Level Dependent (BOLD) Activation CONTRASTS (in Prespecified Regions of Interest (ROI) in VOXELS | IBS-Low Somatization | Right insula activation contrast, Montreal Neurological Institute x,y,z coordinates (27, -1.5, 15) | -0.09 | Standard Deviation 0.06 | arbitrary unit |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | IBS-High Somatization (Open Label Desipramine) | 10 | |
| Overall Study | STARTED | IBS-Low Somatization (Open Label Desipramine) | 8 | |
| Overall Study | COMPLETED | IBS-High Somatization (Open Label Desipramine) | 5 | |
| Overall Study | COMPLETED | IBS-Low Somatization (Open Label Desipramine) | 4 | |
| Overall Study | NOT COMPLETED | IBS-High Somatization (Open Label Desipramine) | 5 | |
| Overall Study | NOT COMPLETED | IBS-Low Somatization (Open Label Desipramine) | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | IBS-High Somatization | 0 | 10 |
| Total, all-cause mortality | IBS-Low Somatization | 0 | 8 |
| Total, all-cause mortality | Healthy Controls | 0 | 15 |
| Total, other adverse events | IBS-High Somatization | 0 | 10 |
| Total, other adverse events | IBS-Low Somatization | 0 | 8 |
| Total, other adverse events | Healthy Controls | 0 | 15 |
| Total, serious adverse events | IBS-High Somatization | 0 | 10 |
| Total, serious adverse events | IBS-Low Somatization | 0 | 8 |
| Total, serious adverse events | Healthy Controls | 0 | 15 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00880594
GET https://conductscience.org/api/trials/v1/NCT00880594/registered